PCaProTreat is an EU-funded translational research project to define molecularly-driven drug targets and therapeutic agents for Prostate Cancer.
PCaProTreat Brochure
PCaProTreat Brochure is available for download from here.
News
-
"Reference to the PCaProTreat Project in Research Executive Agency (European Commission) brochure under section “Exceptional Career Paths"
Highlight on the PCaProTreat project in the brochure devoted to MSCA success stories, entitled:
“MARIE SKŁODOWSKA-CURIE ACTIONS UNDER THE SEVENTH FRAMEWORK PROGRAMME FOR RESEARCH AND TECHNOLOGICAL DEVELOPMENT: A TASTE OF SUCCESS”
More information available from here (see page 24).
-
"A 'molecular' look at prostate cancer boosts treatment options"
The Article on PCaProTreat is now published online under EC Research Success Stories.
More information available from here.
-
Poster presentation at 26th Meeting of the EAU Section of Urological Research (ESUR), October 2019
"Proteomics-driven therapeutic agents for Prostate Cancer"
More information available from here.
-
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer
Host's institution collaborative study entitled “CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer” was awarded in 13. Nordkongress Urologie in Hamburg (13 – 15 June 2019)
-
New Special Issue in Proteomics Clinical Applications: "Clinical Proteomics on the Way Towards Implementation"
-
Interesting video on "Personalized medicine enabled by Proteomics"
-
We support personalised medicine for Prostate Cancer
Host Institution was nominated for Innovationspreis Niedersachsen 2018. More information available here.
PCaProTreat is a Marie Sklodowska Curie Actions (MSCA) Individual Fellowship programme funded by the European Commission (H2020-MSCA-IF-2017-800048).
